{"page_content": "Corporate Governance Best Practices\nWe have taken great strides over recent years to implement corporate governance best \npractices, often acting ahead of the curve in terms of our industry peers and the Russell \n3000, and through a thoughtful and responsive shareholder engagement program.\nMajority Voting\nIn 2015, we adopted a majority voting \nstandard with a director resignation policy.Board and Committee \nRefreshment\nWe added Linda Maxwell, MD as a new \ndirector in 2020, joining three new women \ndirectors added over the last eight years. \nAs part of our Board refreshment strategy \nand to increase the diversity of voices on \nour Board committees, we refreshed our \nCompensation Committee, Nominating \nand Governance Committee, and Audit \nCommittee composition in 2020.\nOur four newest directors also bring strong \nsustainability backgrounds. In 2021, we \namended the Nominating and Governance \nCommittee\u2019s charter to expressly include \nESG oversight.Board Destaggering\nIn 2020, we began a destaggering process \nfor director elections. Going forward, \ndirectors will be elected to one-year terms.\nProxy Access\nIn 2015, we adopted a market-standard \nform of proxy access.\nOverboarding\nWe reduced our overboarding limit to \nfour public company boards in 2020 (down \nfrom the previous limit of five), in direct \nresponse to shareholder feedback.Board Risk Oversight\nWe take risk oversight very seriously. Our Board committees each tackle various risks facing \nour company to ensure management is focused on identifying and mitigating the material \nrisks to our company.\nBoard Committee Key Risk Oversight Areas\nNominating and Governance \nCommitteeEnterprise risk management system and corporate \ncompliance program; PBC/ESG activities\nAudit Committee Auditing, accounting, and financial matters, as well \nas cybersecurity\nCompensation Committee Compensation programs, as well as diversity and \nother human capital priorities.\nLearn more about our Enterprise Risk Management program on page 56.\nUseful Resources\nProxy Statement\nCorporate Governance websiteAnnual Report\nBoard of Directors page \nUNITED STATES\nSECURITIES AND EXCHANGE COMMISSION\n WASHINGTON, D.C. 20549\nFORM 10-K  \n(Mark One)  \n\u2612 ANNUAL REPORT PURSUANT TO SECTION\u00a013 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF\u00a01934.\nFor the fiscal year ended December\u00a031, 2021\nOR\n\u2610 TRANSITION REPORT PURSUANT TO SECTION\u00a013 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF\u00a01934.\nFor the transition period from\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0to\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nCommission file number 0-26301\nUnited Therapeutics Corporation  \n (Exact Name of Registrant as Specified in Its Charter)\nDelaware 52-1984749\n(State or Other Jurisdiction of\nIncorporation or Organization)(I.R.S. Employer\nIdentification No.)\n1040 Spring Street, Silver Spring, MD 20910\n(Address of Principal Executive Offices) (Zip Code)\n(301) \u00a0608-9292  \n Registrant\u2019s Telephone Number, Including Area Code\nSecurities registered pursuant to Section\u00a012(b) of the Act:\nTitle of each class Trading Symbol(s) Name of each exchange on which registered\nCommon Stock, par value $.01 per share UTHR Nasdaq Global Select Market\nSecurities registered pursuant to Section\u00a012(g) of the Act:\nNone\n (Title of Class)\nIndicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule\u00a0405 of the Securities Act.\u00a0\u00a0\u00a0\u00a0 Yes\u00a0\u2612\u00a0\u00a0\u00a0\u00a0No\u00a0\u2610\nIndicate by check mark if the registrant is not required to file reports pursuant to Section\u00a013 or Section\u00a015(d) of the Act.\u00a0\u00a0\u00a0\u00a0Yes\u00a0 \u2610\u00a0\u00a0\u00a0\u00a0No\u00a0\u2612\nIndicate by check mark whether the registrant (1)\u00a0has filed all reports required to be filed by Section\u00a013 or 15(d) of the Securities Exchange Act of \n1934 during the preceding 12\u00a0months (or for such shorter period that the registrant was required to file such reports), and (2)\u00a0has been subject to \nsuch filing requirements for the past 90\u00a0days.\u00a0\u00a0\u00a0\u00a0 Yes\u00a0\u2612\u00a0\u00a0\u00a0\u00a0No\u00a0\u2610\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to \nRule\u00a0405 of Regulation\u00a0S-T (\u00a7232.405 of this chapter) during the preceding 12\u00a0months (or for such shorter period that the registrant was required to \nsubmit such files).\u00a0\u00a0\u00a0\u00a0 Yes\u00a0\u2612\u00a0\u00a0\u00a0\u00a0No\u00a0\u2610\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, \nor an emerging growth company. See the definitions of \u201clarge accelerated filer,\u201d \u201caccelerated filer,\u201d \u201csmaller reporting company,\u201d and \u201cemerging \ngrowth company\u201d in Rule\u00a012b-2 of the Exchange Act.\nLarge accelerated filer \u2612 Accelerated filer \u2610\nNon-accelerated filer \u2610 Smaller reporting company \u2610\nEmerging growth company\u00a0 \u2610\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with \nany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \u2610\nIndicate by check mark whether the registrant has filed a report on and attestation to its management\u2019s assessment of the effectiveness of its \ninternal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm \nthat prepared or issued its audit report.  \u2612\nIndicate by check mark whether the registrant is a shell company (as defined in Rule\u00a012b-2 of the Act).\u00a0\u00a0\u00a0\u00a0Yes\u00a0 \u2610\u00a0\u00a0\u00a0\u00a0No\u00a0\u2612\nThe aggregate market value of the Common Stock held by non-affiliates of the registrant, based on the closing price on June\u00a030, 2021 , as reported \nby the Nasdaq Global Select Market was approximately $7,912,099,590 .\nThe number of shares outstanding of the issuer\u2019s common stock, par value $0.01 per share, as of February\u00a017, 2022 , was 45,132,102 . \nDOCUMENTS INCORPORATED BY REFERENCE\nPortions of the registrant\u2019s definitive proxy statement for the registrant\u2019s 2022  annual meeting of shareholders scheduled to be held on June\u00a027, \n2022 , are incorporated by reference in Part\u00a0III of this Form\u00a010-K.\nWHO  WE ARE\nOUR APPROACH TO \nSUSTAINABILITY\nOUR PATIENTS\nOUR PEOPLE\nOUR PHYSICIANS \nAND PAYERS\nOUR PLANET AND \nCOMMUNITIES\nOUR PRINCIPLES AND  \nOTHER PRIORITIES\nREPORTING \nINDEXESA MESSAGE FROM \nOUR CEO\n50\nOUR PRINCIPLES AND  \nOTHER PRIORITIES\n", "metadata": {"source": "NASDAQ_UTHR_2022.pdf", "page": 49, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}